Consensus Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
3.61 ^USD	0.00%		+10.06%	+572.25%

May. 14	Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target	MT
May. 02	Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Elevation Oncology, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3a63f90ffedb3f.rflUlIo3ZcqpRoHzgr-49D7YamHDoDt7KyNDae_nCR8.laAg9rJ8EYH2AsqhytP_vVCUGxeWyHhDTUBuEL6VOVPDgwfg_HVRsM414g~0abf9a602879d83ce412ece89d4e32f7

Analyst Recommendations on Elevation Oncology, Inc.

Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target	May. 14	MT
Wedbush Raises Elevation Oncology's PT to $8 From $5, Continues to See 'Intriguing' Opportunity in Shares; Keeps Outperform Rating	Mar. 07	MT
JMP Securities Starts Elevation Oncology' With Market Outperform Rating	Mar. 01	MT
HC Wainwright Adjusts Elevation Oncology Price Target to $6 From $1.50, Maintains Buy Rating	Feb. 20	MT
Wedbush Trims Elevation Oncology's Price Target to $5 From $6, Keeps Outperform Rating	23-08-04	MT
Looming CPI, Fed Rate Decision Drive Quiet Premarket Action for US Equity Futures	23-06-09	MT
Wedbush Lifts Elevation Oncology's Price Target to $6 From $4 on 'Impressive' Data, Keeps Outperform Rating	23-06-05	MT
SVB Securities Upgrades Elevation Oncology to Outperform From Market Perform, Adjusts Price Target to $8 From $5	23-05-30	MT
Wedbush Lowers Elevation Oncology's Price Target to $4 From $6 After Announced Reprioritization of Development Efforts, Keeps Outperform Rating	23-01-23	MT
SVB Securities Cuts Price Target on Elevation Oncology to $1 From $2, Maintains Market Perform Rating	23-01-09	MT
JPMorgan Downgrades Elevation Oncology to Underweight From Neutral	22-11-10	MT
SVB Securities Downgrades Elevation Oncology to Market Perform From Outperform, Adjusts Price Target to $2 From $11	22-11-07	MT
Wedbush Lowers Elevation Oncology's Price Target to $6 From $8, Updates Expectations Around Future Equity Raises; Keeps Outperform Rating	22-11-04	MT
HC Wainwright Assumes Elevation Oncology at Buy with $7.50 Price Target	22-09-19	MT
JPMorgan Downgrades Elevation Oncology to Neutral from Overweight	22-08-08	MT
Wedbush Adjusts Price Target on Elevation Oncology to $8 From $15; Outperform Rating Kept	22-07-29	MT
Wedbush Adjusts Elevation Oncology's Price Target to $15 From $21, Keeps Outperform Rating	22-05-06	MT
Wedbush Cuts Elevation Oncology's Price Target to $21 From $27, Citing 'Financing Environment;' Outperform Rating Kept	22-03-04	MT
HC Wainwright Initiates Coverage on Elevation Oncology With Buy Rating, $12 Price Target	21-12-23	MT
ELEVATION ONCOLOGY : JPMorgan Starts Elevation Oncology at Overweight with $24 Price Target	21-07-20	MT
ELEVATION ONCOLOGY : SVB Leerink Starts Elevation Oncology at Outperform With $20 Price Target	21-07-20	MT
ELEVATION ONCOLOGY : Wedbush Starts Elevation Oncology at Outperform With $27 Price Target	21-07-20	MT
ELEVATION ONCOLOGY : Cowen Initiates Coverage on Elevation Oncology With Outperform Rating	21-07-20	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.61 USD

Average target price

7.8 USD

Spread / Average Target

+116.07%

High Price Target

10 USD

Spread / Highest target

+177.01%

Low Price Target

6 USD

Spread / Lowest Target

+66.20%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Elevation Oncology, Inc.

Stephens Inc.
Wedbush
JMP Securities
HC Wainwright
SVB Securities LLC
JPMorgan Chase
Cowen
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar